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About this Report 
About NLCAHR 
The Newfoundland & Labrador Centre for Applied 
Health Research, established in 1999, contributes to the 
effectiveness of health and community services in 
Newfoundland and Labrador and to the physical, social, 
and psychological wellbeing of its population. NLCAHR 
accomplishes this mandate by building capacity in 
applied health research, supporting high-quality 
research, and fostering the effective use of research 
evidence by decision makers and policy makers in the 
provincial healthcare system.  
 
About the Contextualized Health 
Research Synthesis Program 
 
In 2007, NLCAHR launched the Contextualized Health 
Research Synthesis Program (CHRSP) to provide research 
evidence that would help guide decision makers in the 
provincial health system on issues of pressing interest to 
Newfoundland and Labrador.  Instead of conducting 
original research, CHRSP analyzes findings from high 
level research already conducted in the subject area, 
such as systematic reviews, meta-analyses and health 
technology assessments. Findings are then synthesized 
and subjected to a systematic process of contextual-
ization:  they are analyzed in terms of their applicability 
to the conditions and capacities of the unique context of 
Newfoundland and Labrador.  Our contextual analysis in-
cludes assessing the specific forms an issue may take in 
this province as well as the applicability of any proposed 
solutions and methods to locally available resources, in-
frastructure, human resources, cultural conditions and 
financial capacities.  CHRSP uses a combination of ex-
ternal experts and local networks to carry out and con-
textualize the research synthesis and to facilitate the 
uptake of the results by research users. CHRSP focuses 
on three types of projects: health services/ health policy 
projects, health technology assessment (HTA) projects, 
and projects that combine the two to examine processes 
for the organization or delivery of care involving a health 
technology. 
 
About Our Partners  
For this project, NLCAHR partnered with Eastern Health 
and the Canadian Agency for Drugs in Technology and 
Health (CADTH).  Senior administrators from Eastern 
Health proposed the research topic while CADTH helped 
the research team refine the research question.  CADTH 
also identified relevant research literature, appraising 
and synthesizing the evidence in a peer-reviewed report. 
The work by CADTH has been published independently 
and is available for viewing on the NLCAHR website: 
www.nlcahr.mun.ca/chrsp.  The CHRSP Project Team, 
with input from key stakeholders throughout the 
province, provided additional analysis and context-
ualization of the CADTH results for Newfoundland and 
Labrador.  This project was funded in part by the 
Canadian Institutes of Health Research (CIHR)- Institute 
of Health Services and Policy Research (IHSPR). 
 
Who Should Read This Report? 
This report provides a synthesis of the relevant research-
based evidence on the clinical and cost effectiveness of 
hyperbaric oxygen therapy for difficult wound healing, 
including diabetic foot ulcers, pressure ulcers, delayed 
radiation-induced injury, thermal burns, skin grafts and 
flaps, and revascularization after organ transplantation. 
 
This report is intended to inform and assist decision 
makers in the Eastern Health Regional Health Authority, 
the Newfoundland and Labrador Department of Health 
and Community Services and the province’s three other 
Regional Health Authorities on the treatment and 
management of patients with certain non-healing (i.e., 
difficult) wounds. The findings of our synthesis are 
specifically interpreted for the context of Newfoundland 
and Labrador.  Decision makers from other jurisdictions, 
especially those with similar potential clients, geography 
and resources, may also find the content helpful.   The 
report includes explanations of research terms and 
technical language; as such, there is no need to have a 
specialized medical or health background to understand 
its content.
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Acronyms 
 
  
AMSTAR Assessment of Multiple Systematic Reviews 
CADTH Canadian Agency for Drugs and Technology in Health 
CI Confidence Interval 
CIHR-ISPR Canadian Institutes of Health Research – Institute of Health Services and Policy Research 
DHCS Department of Health and Community Services (Government of Newfoundland and Labrador) 
DRII Delayed Radiation Induced Injury 
ECHM European Committee for Hyperbaric Medicine 
HBOT Hyperbaric Oxygen Therapy 
HIF Hypoxia-Inducible Factors 
HTA Health Technology Assessment 
HTIS Health Technology Information Systems (CADTH) 
ICU Intensive Care Unit 
IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency 
in Health Care) Germany 
KTE Knowledge Transfer and Exchange 
MEDICOR Centre for Offshore and Remote Medicine (Memorial University) 
MeSH Medical Subject Headings 
MUN Memorial University 
NLCAHR Newfoundland and Labrador Centre for Applied Health Research 
NNT Number Needed to Treat 
PR Primary Research 
QALY Quality Adjusted Life Years 
QoL Quality Of Life 
RCT Randomized Controlled Trials 
RHA Regional Health Authority 
RR Relative Risk 
RT Respiratory Therapist 
SOMA-
LENT 
Subjective, Objective, Management, and Analytic (SOMA) measures of Late Effects on Normal Tissue 
(LENT) from radiation therapy 
UHMS Undersea and Hyperbaric Medical Society 
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Glossary 
Adjunctive therapy A supplementary therapy that improves the outcomes of a primary therapy or 
procedure. 
Adjunctive treatment An assistive treatment that does not act directly on the target pathology. 
AMSTAR An 11-item instrument used to assess the methodological rigor of systematic reviews. 
Apoptosis Programmed cell death. 
Collagen synthesis Cellular formation of collagen, a common connective tissue in the body. 
Confidence interval (CI) A measure of the reliability of an estimate. A CI specifies a range within which the true value of 
the estimated parameter is expected to lie. For ratios, if the CI spans the 1 value, e.g. 0.8 to 1.3 
for a relative risk, the comparison in question is not statistically significant. Likewise, if the CI 
spans the 0 value, e.g. -2.4 to 3.2 for the difference in a test score, than the comparison in 
question is also not statistically significant. When the CI spans those critical values, the studied 
groups cannot be considered different from one another on the measure in question. 
Costs-effectiveness study A study in which the monetary costs of an intervention are considered in terms of a 
single common health outcome that is measured in natural units. Examples of such 
outcomes include: the number of years with full mobility gained or the number of 
placements in long-term care deferred. 
Cost-utility study A study in which the monetary costs of an intervention are considered in terms of a 
single outcome, or considered in terms of multiple outcomes that are weighted or valued 
in relative terms. The combined outcome is measured in units that capture both the 
quantity and quality of the effects of the intervention, with the most common measure 
being the quality-adjusted life-year or QALY. 
Cytokine A type of protein that acts as a signal between cells involved in immune response. 
Dive A single treatment session in a hyperbaric oxygen chamber. A treatment course for hyperbaric 
oxygen therapy may involve multiple dives taken over a period of time. 
Effect size A measure of the strength of a relationship between two variables, for example between a 
treatment for a health condition and recovery from that health condition. Effect sizes may be 
quantified by a range of different measures, including correlations, differences in means and 
relative risks. 
Effectiveness The ability of an intervention to produce the desired beneficial effect in actual usage. 
Efficacy The ability of an intervention to produce the desired beneficial effect in expert hands and 
under ideal circumstances. 
Fibroblast Cells that make connective tissues, e.g., collagen. 
Grey literature Research that is published non-commercially, that may include reports carried out by 
governments, health authorities and not-for-profit associations. 
Health Technology 
Assessment (HTA) 
A multidisciplinary field of policy analysis that studies the medical, social, ethical and 
economic implications of development, diffusion, and use of health technology. 
Hemoglobin A blood-protein that contains iron and serves as the principal carrier of oxygen in the 
blood. 
HIF Hypoxia-inducible factors, proteins that bind to specific DNA sequences to promote cell 
survival in hypoxic conditions. 
Hyperbaric Of, relating to, producing, operating, or occurring at pressures higher than normal 
atmospheric pressure. 
Hypoxia A deficiency of oxygen reaching the tissues and cells of the body. 
Incidence A measure of the number of new cases of a disease in a population over a period of time. 
Ischemia Restriction of blood supply, and therefore oxygen, to tissue that leads to damage and/or 
dysfunction. 
Meta-analysis A type of systematic review that uses statistical techniques to quantitatively combine the 
findings from previous primary research studies. 
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Monocyte A white blood cell involved in immune responses; during an immune response, 
monocytes will become macrophages or dendritic cells . Macrophages destroy damaged 
tissue and pathogens, and stimulate additional immune responses. Dendritic cells 
process and display proteins from pathogens, and coordinate additional immune 
responses. 
Neutrophil A white blood cell involved in immune responses; during an immune response, 
neutrophils will congregate at the site of inflammation, attack micro-organisms and 
stimulate additional immune responses. 
Number needed to treat 
(NNT) 
A measure of treatment effectiveness. NNT is the number of patients that need to be 
treated in order to prevent one additional adverse outcome among those patients. An 
ideal treatment would have a NNT equal to 1, meaning that each patient treated will not 
experience the adverse outcome in question. The greater the NNT, the less effective the 
treatment in question. 
Osteoradionecrosis Necrosis/tissue death of bone as a result of exposure to radiation. 
Partial pressure The pressure exerted by one component gas in a mixture of gasses. A gas may also be 
partly dissolved in a liquid; in this case, the partial pressure is the pressure exerted by the 
un-dissolved or gaseous component of the gas when in a state of equilibrium (where the 
concentration of the dissolved gas is constant). 
Prevalence A measure of the number of existing cases of a disease in a population at a particular 
time. 
Proctitis Inflammation of the rectum or anus. 
Progenitor The originator of a type of cell, a stem cell. 
Primary research Research that involves the collection and analysis of data from actual participants, as 
opposed to the combination of such research (i.e. higher level studies) or secondary 
analyses of previously collected data. 
QALY A measure that combines time and an assessment of quality of life. QALY stands for 
“quality adjusted life year.” A QALY unit is based on a scale that considers one year of life 
lived in perfect health worth 1 QALY. A year of life that is lived in a state of less than 
perfect health is worth less than 1 QALY. The quality of life is quantified as “the utility 
value,” a measure of the state of health of the person in question. To get a QALY value, 
the utility value is multiplied by the years lived in that state: UTILITY x TIME = QALY. 
QALYs are expressed in terms of “years lived in perfect health.” For example, half a year 
lived in perfect health is equivalent to 0.5 QALYs, the same as 1 year of life lived in a 
compromised state of health with utility 0.5 (Drummond, Sculpher, Torrance, O’Brien, & 
Stoddart, 2005). 
Randomized controlled 
trial 
A type of primary research in which participants are randomized with regards to 
treatment, with the objective of balancing the impacts of confounding factors that may 
exist among the participants. 
Rectitis Another term for proctitis. 
Relative risk (RR) A measure of the likelihood that an exposure will have a particular outcome. In the case 
of health treatments, RR is the ratio of the probability of an outcome occurring in a 
treated group compared to the probability of its occurring in an untreated group. For 
example, for diabetic foot ulcers treated with HBOT and major amputation as the 
outcome, RR is expressed as the ratio of the probability that a treated patient will not 
require a major amputation to the probability that an untreated patient will require an 
amputation:  
o RR of 1 means that there is no difference between the treated and untreated groups;  
o RR of less than 1 means the patients who received the treatment are less likely to 
require a major amputation; 
o RR of greater than 1 means patients are more likely to require a major amputation. 
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Skin graft Skin for grafting that is wholly removed from one part of the body and transferred to another 
site. 
Skin flap Skin for grafting that is only partially removed from one part of the body so that it retains 
its own blood supply during transfer to another site. 
SOMA-LENT A scale to measure Late Effects on Normal Tissue (LENT) from radiation therapy, from 
several perspectives: Subjective, Objective, Management, and Analytic (SOMA). 
Systematic review A literature review, focused on a specific and explicit research question that tries to identify, 
appraise, select and synthesize published and unpublished research evidence relevant to that 
question. 
Tension The partial pressure of a gas that is dissolved in blood. 
Units of measurement 
 
o atm (atmosphere): a unit of pressure equal to the average pressure of the atmosphere 
at sea level. One atmosphere is defined as 101.325 kPa or 760 mm Hg. 
o bar (bar): a unit of pressure used to describe compressed air equipment, including that 
used in HBOT. One bar is defined as 100.0 kPa and is also referred to as standard 
pressure. 
o Gy (gray): unit of absorbed energy from ionizing radiation. One gray is defined as the 
absorption of one joule of ionizing radiation by one kilogram of matter (usually human 
tissue). 
o kPa (kilopascal): a unit of pressure. One kilopascal is defined as 1000 pascals or 1000 
N/m2 (newtons per square meter, a measure of force applied over an area). 
o mm Hg (torr): a unit of pressure.  One torr is defined as 133.3 pa. The ‘mm’ refers to 
millimeters and the ‘Hg’ refers to mercury. This is a holdover from measuring devices 
that used a column of mercury to measure pressures, for example, barometers or 
sphygmomanometers (the arm-cuff blood pressure instrument). 
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The Research Question
 
What does the scientific literature tell us about the clinical and economic 
effectiveness of hyperbaric oxygen treatment for difficult wound healing (i.e., 
diabetic foot ulcers, pressure ulcers, delayed radiation-induced injury, thermal 
burns, skin grafts, and revascularization after organ transplantation) considering the 
expected patient populations and given the social, geographic, economic and political 
contexts of Newfoundland and Labrador? 
Key Messages from this Report 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“ 
” 
7 
 
1. Research evidence supports HBOT as both clinically-effective and cost-effective (from a 
societal perspective) for diabetic foot ulcers. 
2. Research evidence supports HBOT as clinically-effective for delayed radiation-induced 
injuries in the head, neck and pelvic regions. 
3. There is insufficient evidence to support or contradict HBOT treatment for pressure ulcers, 
delayed radiation-induced injuries other than those in the head, neck and pelvic regions, 
severe thermal burns, skin grafts and skin flaps, or revascularization after organ transplant-
ation.  
4. The cost effectiveness of HBOT for appropriate non-healing wounds will increase as the 
number of patients treated increases. The incidence of health conditions that can result in 
non-healing wounds is expected to increase in Newfoundland and Labrador, producing a 
greater number of patients who would be appropriate candidates for HBOT. 
5. For difficult wounds shown to be responsive to HBOT (e.g., diabetic foot ulcers and 
radiation proctitis) the appropriate and timely referral of patients is expected to improve 
with greater integration of wound-care management into existing chronic and acute health 
services programs. This, in turn, is expected to increase the clinical and cost-effectiveness 
of HBOT treatment for those conditions.  
6. Overall, research evidence for the clinical and cost-effectiveness of HBOT for difficult (non-
healing) wounds is limited. As a result, future studies are expected to have a significant 
impact on the evidence base for or against HBOT for a number of non-healing wound 
conditions.  Furthermore, Eastern Health may benefit from establishing liaisons with other 
more established HBOT units across the country to share evidence and clinical expertise. 
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Background 
The hyperbaric oxygen therapy (HBOT) facilities for 
Newfoundland and Labrador were originally located 
in, and administered by, the Centre for Offshore 
and Remote Medicine (MEDICOR). MEDICOR was 
established in 1982 as a research centre within the 
Faculty of Medicine at Memorial University. The 
initial mandate of MEDICOR was to conduct health 
research related to diving and related industries. 
The main focus of operation for its HBOT facilities 
was research. Over time, HBOT was increasingly 
used for clinical emergency cases such as 
decompression illness and carbon monoxide 
poisoning.  The recommended clinical applications 
of HBOT for non-emergency cases also increased, 
resulting in significant additional demand. (1,2)  
The shift in focus from research activity to clinical 
applications was conducted on an ad hoc basis with 
limited staff and resources. By 2008, research 
involving HBOT had decreased effectively to 
nothing.  Staffing issues then forced the closure of 
the HBOT facility in February 2009. In September 
2009, Eastern Health and Memorial University 
announced the transfer of ownership of the HBOT 
facilities to Eastern Health. Eastern Health and 
Memorial University established an agreement in 
March 2010 whereby Eastern Health would take 
formal responsibility for the HBOT facility for all 
clinical case work, while Memorial University would 
still have access to the equipment for research and 
educational purposes. (1,2) 
As a result, Eastern Health is now developing policy 
for the clinical use of the HBOT facility.  It has 
increased HBOT capacity, in terms of both infra-
structure and dedicated human resources. Eastern 
Health intends to continue to increase capacity to 
meet the expected growth in demand for clinical 
HBOT services. In partnering with CHRSP, Eastern 
Health is seeking research-based evidence that will 
provide guidance about the clinical and cost 
effectiveness of HBOT for difficult wounds, health 
conditions that require attention in the province. 
For this project, NLCAHR partnered with Eastern 
Health and the Canadian Agency for Drugs in 
Technology and Health (CADTH). The CHRSP Project 
Team included senior administrators from Eastern 
Health (who proposed the topic), local clinical and 
research experts in HBOT and difficult wound 
healing, and CHRSP staff at NLCAHR (see “The 
Research Team,” page 2, for details). The CHRSP 
Project Team and CADTH refined the original 
research question for this project and produced the 
following:  
What does the scientific literature tell us about 
the clinical and economic effectiveness of 
hyperbaric oxygen treatment for difficult 
wound healing (i.e., diabetic foot ulcers, 
pressure ulcers, delayed radiation-induced 
injury, thermal burns, skin grafts and flaps, and  
revascularization after organ transplantation) 
considering the expected patient populations 
and given the social, geographic, economic and 
political contexts of Newfoundland and 
Labrador? 
CADTH was tasked with searching for and iden-
tifying the relevant research literature (see “What 
research did we look for?” on page 15), critically 
appraising the evidence, producing a report 
synthesizing the evidence, and having the results 
peer-reviewed. The work by CADTH has been 
published as an independent report and it forms 
the basis of the NLCAHR project. (3) The CHRSP 
Project Team took the CADTH results and, with 
input from key stakeholders throughout the 
province, provided additional analysis and 
contextualization for Newfoundland and Labrador. 
8 
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What is hyperbaric oxygen therapy? 
 
In essence, hyperbaric oxygen therapy (HBOT) 
consists of delivering to patients pure oxygen gas 
(O2) at pressure levels higher than normal pressure.  
HBOT delivers 100% O2 to the patient, compared 
with the average O2 concentration in air at sea level, 
which is 21%.  Hyperbaric oxygen therapy is used to 
treat both emergency and chronic health 
conditions.  HBOT was first used and developed for 
emergency conditions such as decompression 
illness or carbon monoxide poisoning (see Table 1. 
Page 12  for more examples).  Emergency HBOT is 
immediately administered to the patient and 
generally consists of one dive1 that may last several 
hours. HBOT is also used to treat chronic health 
conditions such as diabetic foot  ulcers or some 
types of radiation-induced necrosis. In these cases, 
HBOT is an adjunctive therapy that typically consists 
of many shorter dives (60-90 minutes) administered 
once daily or less, over weeks or months.  New 
research suggests, though does not yet prove, that 
HBOT may be used for the pre-treatment of tissue 
and organs prior to surgery in order to improve 
their resistance to ischemic and other trauma. (7-9) 
Airtight chambers are used to produce the higher 
pressures and they come in two basic types of 
construction.  
 
The first type is a multi-place chamber that can acc-
ommodate one or more patients at a time. Multi-
place chambers are designed as sealed rooms. The 
space inside the chamber is pressurized with com-
pressed normal air to maintain the higher than nor-
mal pressures. Patients then breathe pure press-
urized oxygen through a mask or a hood. In this de-
sign, patients absorb oxygen exclusively through the 
lungs by breathing. Most of the equipment and att-
endant staff are located inside the multi-place 
chamber along with the patients. The additional 
space for staff makes multi-place chambers a good 
option for patients with complex case management 
and multiple co-morbidities requiring monitoring by 
specialists. By virtue of involving several individuals 
working together, multi-place chambers provide an 
effective opportunity for team training. 
All HBOT regulatory bodies recommend limits on 
hyperbaric exposure, time for decompression, and 
restrictions on certain activities, such as flying or 
travel in mountainous regions, for attendant staff. 
(4)  In practice, this usually means that attendant 
staff does not participate in more than one dive per 
day (E. Carew, Patient Care Co-ordinator, Hyper-
baric Medicine, Eastern Health, personal commun-
ication, 2011).   
 
 
 
 
 
 
 
9 
Figure 1: Schematic layout of HBOT multi-place chamber in the Health Sciences Centre,  
St. John’s (Wood, 2009) and photo of actual chamber (Memorial University of Newfoundland) 
 _________________________ 
1 
 Hyperbaric medicine often refers to an individual treatment as a ‘dive.’ For the purposes of this report, a single 
course of hyperbaric oxygen therapy is referred to as a ‘treatment.’  A ‘full course of HBOT’ refers to the number of 
treatments prescribed to patients for particular health condition(s). 
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The second type of construction is a mono-place 
chamber, or mono-chamber, that can accommo-
date only one patient.  In some special cases, the 
chamber will accommodate two people (for ex-
ample, a child and parent).  Mono-chambers are 
typically designed as an enclosed bed on which the 
patient reclines. No hoods or masks are worn by the 
patient as with multi-place chambers; instead, pure 
O2 is pumped directly into the chamber at elevated 
pressure. The patient absorbs oxygen through the 
lungs by breathing (5) and by passive diffusion 
through the skin and open wounds. (6)   Equipment 
and staff are located outside the mono-chamber. 
With both constructions, the 
combination of elevated 
pressure and the higher 
concentration of inhaled O2 
causes an increase in the 
amount of oxygen that is 
absorbed by the patient.  The 
principal transport mechanism 
for oxygen is blood.  Approx-
imately 98.5% of inhaled 
oxygen is bound to the blood-borne protein 
hemoglobin. Hyperbaric oxygen does not increase 
the amount of hemoglobin-bound oxygen, since 
hemoglobin is normally saturated with oxygen 
already. The remaining 1.5% of oxygen in the blood 
is dissolved in the liquid component of blood, 
plasma. At 1 atm2 of pressure, and breathing 100% 
O2, the dissolved amount of oxygen in blood plasma 
is approximately 1.5 g/dL.  An increase in pressure 
to 3 atm will raise this to 6.0 g/dL, which, by itself, is 
enough oxygen to support resting cellular 
metabolism. (5)  
In mono-chamber HBOT, the body surface of the 
patient is also exposed to 100% O2. In normal 
conditions, the O2 tension in wounds typically drops 
from 60 mm Hg to 20-35 mm Hg after one week.      
 
A standard HBOT treatment of 100% O2 at 3 atm for 
20 minutes will raise O2 in wounds, on average, to 
nearly 400 mm Hg. (6) 
Oxygen plays multiple critical roles in wound 
metabolism. Research has advanced to the point 
where complex biochemical and physiologic 
pathways can be investigated at the molecular 
level. These analytic methods provide evidence for 
ways in which HBOT effects wound metabolism. The 
most important mechanisms are related to how 
oxygen influences the levels of cytokines, which are 
intercellular mediators of immune function. Recent 
evidence indicates that particular 
combinations of cytokines, or 
‘cytokine signatures,’ trigger the 
production of specific proteins and 
the expression of specific genes 
involved in wound metabolism. The 
oxygen level influences the body’s 
subsequent immune reaction to a 
wound. The oxygen level may also 
affect tissues and the immune system 
prior to sustaining a wound: it may 
reduce the severity of tissue damage and the 
degree of immune-related inflammation. HBOT 
influences cytokine signatures in several complex 
and inter-related ways that are described 
schematically in Figure 2. (5-13) 
Very few adverse effects from HBOT have been 
reported.  Barotrauma, damage as a result of 
sudden pressure changes, may affect the middle ear 
(less than 2% of cases), cranial sinuses, teeth or 
lungs (very rare). Reversible myopia is the most 
common side-effect and is normally a temporary 
result of the effects of oxygen on the ocular lens. 
Other types of oxygen toxicity are possible, but very 
rare. The remaining adverse effects involve 
discomfort, including claustrophobia, chest 
tightness and cough. (5,14)  
 
10 
_________________________ 
2
 Gas pressure is measured in several different units depending on the context. Definitions for the units used in this report 
may be found in the Glossary under “Units of measurement,” on page 6. 
 
Oxygen plays multiple critical 
roles in wound metabolism. 
Research has advanced to the 
point where complex biochemical 
and physiologic pathways can be 
investigated at the molecular 
level. These analytic methods 
provide evidence for ways in 
which HBOT effects wound 
metabolism. 
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Hyperbaric oxygen therapy in Canada
 
At present, the principal regulatory process for 
HBOT in Canada is the issuing of medical device 
licenses by Health Canada. (15,16)  Such licenses are 
required to import or sell HBOT chambers.  
According to Health Canada, (17) HBOT medical 
device licenses will only be issued if the chamber(s) 
will be used to treat one or more health conditions 
approved by the US-based Undersea and Hyper- 
baric Medical Society (UHMS) (See Table 1). UHMS 
considers research evidence in developing the list of 
approved conditions through a committee-based 
approval process. Multiple Canadian and inter-
national jurisdictions, including national ministries 
of health and multi-national organizations, have a 
high level of agreement (though not unanimity) 
with the UHMS list of conditions.   
Figure 2: Mechanisms and effects of HBOT on non-healing wounds. (5-13) 
11 
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Legend:  
 Bold:  Condition is studied in this report 
 Y:  Condition is eligible for HBOT treatment (and public system reimbursement) 
 N:  Condition is specifically designated on exclusion list (and ineligible for public system reimbursement) 
 [blank]:  Condition is not indicated as eligible for HBOT (and ineligible for public system reimbursement) 
Cases: 
 E:   Emergency treatment cases  
 A:   Adjunctive therapy cases 
 P:   Pre-treatment cases 
Jurisdictions: 
 UHMS:  Undersea and Hyperbaric Medical Society  
 ECHM:  European Committee for Hyperbaric Medicine 
 Countries:  BE Belgium | NL Netherlands | Fr France | UK United Kingdom | US United States (Medicare) | AU Australia 
Notes:  
 Fr* :   No restrictive list in place, any condition is potentially eligible for HBOT treatment;  
        UK** :  No explicit list of eligible conditions in place at national level, District Health Authorities determine the health  
conditions that will be covered and these are usually based on UHMS 
 
  
 Condition Case UHMS ECHM BE NL FR* UK** US AU 
U
H
M
S
 a
pp
ro
ve
d 
Clostridal myositis and myonecrosis (gas gangrene) E Y Y Y Y Y* Y** Y Y 
CO poisoning E Y Y Y Y Y* Y** Y Y 
Decompression illness & gas embolism E Y Y Y Y Y* Y** Y Y 
Diabetic foot  ulcers A Y Y Y Y Y* Y** Y Y 
Hemorrhagic cystitis after irradiation A Y Y Y Y Y* Y** Y Y 
Osteoradionecrosis A Y Y Y Y Y* Y** Y Y 
Radiation proctitis & enteritis A Y Y Y Y Y* Y** Y Y 
Chronic refractory osteomyelitis A Y Y Y Y Y* Y** Y 
 
Crush injuries, compartment syndromes, traumatic ischemias E Y Y Y Y Y* Y** Y 
 
Larynx radionecrosis A Y Y Y Y Y* Y** 
 
Y 
Necrotizing soft tissue infections (flesh-eating disease) E Y Y 
 
Y Y* Y** Y Y 
Skin grafts and myocutaneous flaps A Y Y Y Y Y* Y** Y 
 
Soft tissue radionecrosis A Y Y Y 
 
Y* Y** Y Y 
Intracranial abscess A Y Y 
  
Y* Y** 
  
Pressure ulcers A Y Y 
 
N Y* Y** N 
 
Thermal burns A Y Y 
 
N Y* Y** N 
 
Exceptional blood loss or anemia E Y 
   
Y* Y** 
  
C
on
fli
ct
in
g 
ap
pr
ov
al
 
Acute deafness A 
 
Y Y N 
    
Re-implantation of fingers/extremities P 
   
Y 
    
Acute peripheral arterial insufficiency E 
      
Y 
 
Anoxic encephalopathy E 
 
Y 
 
N 
    
Chronic critical ischemia in case of arteriosclerosis A 
  
Y 
   
N 
 
Cyanide poisoning E 
      
Y 
 
Ischemic ocular disorders/abnormalities A 
 
Y 
 
N 
    
Neuroblastoma Stage IV A 
 
Y 
      
Pneumatosis Cystoides Intestinalis A 
 
Y 
      
 N
ot
 a
pp
ro
ve
d 
or
 d
is
ap
pr
ov
ed
 
Organ storage or transplantation P       N 
 
Acute cerebral oedema, Acute or chronic cerebral vascular 
insufficiency, Aerobic or anaerobic septicemia & infection (non-
clostridial), Arthritic Diseases, Cardiogenic shock, Chronic 
peripheral vascular insufficiency, Exceptional blood loss 
anaemia, Hepatic necrosis, Myocardial infarction, Nonvascular 
causes of chronic brain syndrome, Pulmonary emphysema, 
Senility, Sickle cell anaemia, Smoke inhalation, Systemic 
aerobic infection, Tetanus 
 
 
n/a 
    
  
N 
 
Acute coronary syndrome,  Acute traumatic brain damage, 
Cerebral hypoxia, traumatic or after a stroke, Malign otitis 
externa, Multiple Sclerosis, Radionecrosis of the central 
nervous system, Tinnitus 
 
n/a 
   N     
12 
Table 1: List of approved health conditions for HBOT from multiple jurisdictions 
 
List of Approved Health Conditions for Hyperbaric Oxygen Therapy: Multiple Jurisdictions 
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Within Canada, the provinces have authority over 
which health conditions will be insured for HBOT 
through their public health plans. In practice, the 
provinces follow Health Canada’s UHMS-based 
guidelines. Private clinics must claim that any 
imported HBOT chamber will be used to treat one 
or more of the UHMS-based approved conditions. 
However, once the HBOT chamber has been set up 
and is operational, private clinics are largely 
unregulated.3  There is little to no oversight as to 
which conditions are being treated with HBOT, and 
private clinics are not obliged to follow any 
particular clinical guidelines or standards of 
practice. 
An exhaustive listing of hyperbaric facilities in 
Canada does not seem available at present.  A 
compilation of partial listings originating from 
hyperbaric medicine organizations, the Canadian   
 
Armed Forces, and business directories, indicates 
that there are at least forty-seven HBOT facilities 
operating across the country (see Figure 3 and the 
online Companion Document for details). Fourteen 
facilities exist in hospitals or are otherwise part of 
the public healthcare system. Several significant in-
vestments have reportedly been made to existing 
facilities across Canada in the past ten years, name-
ly at: Vancouver General Hospital (2004), Toronto 
General Hospital (2005), and Hôtel-Dieu de Lévis 
(2012). These investments indicate an increased de-
mand for HBOT capacity for clinical and research 
uses (Evans, W., Chair, Ontario Medical Association 
& Assistant Professor - Department of Anaesthesia, 
Faculty of Medicine, University of Toronto, personal 
communication, 2010). Other HBOT facilities in 
Canada include six that are operated by the Can-
adian Armed Forces and two located in university 
research centers.  
 
 
 
13 
_________________________ 
3
 Private HBOT clinics are regulated only with respect to the operational standards of their HBOT chambers, not what 
conditions their chambers are used to treat. 
Figure 3: HBOT facilities in Canada  
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The remaining twenty-five identified facilities are in 
private clinics that may or may not treat patients on 
behalf of the public healthcare system. Medical 
groups have voiced concern that private clinics are 
using HBOT to treat a number of non-UHMS 
approved conditions (see “Not approved” section in 
Table 1). Additional concerns about private clinics 
include: lack of adequately trained medical staff at 
the clinics, lack of informed consent from patients 
as to the experimental nature of some treatments, 
increased risk of side effects from multiple 
treatments, and the financial exploitation of 
patients with conditions that have been shown 
consistently to not improve with HBOT, e.g., autism, 
cerebral palsy, or Alzheimer’s disease. (18) 
Unlike most medical sub-specialties in Canada,  
there is currently no formal certification for 
physicians to practice hyperbaric medicine.  A 
Canadian chapter of UHMS was recently established 
and one of its first objectives is to initiate a diploma 
program that will be recognized by the Royal 
College of Physicians and Surgeons. Local training is 
available in provinces with HBOT facilities and is 
usually required by regional health authorities. A 
similar situation exists with respect to nurses and 
respiratory therapists involved with HBOT. 
Hyperbaric safety directors and supervisors, key 
non-medical staff at every HBOT facility, are 
required to be certified by the Canadian Standards 
Association (K. LeDez, President, Undersea & 
Hyperbaric Medical Society—Canadian Chapter, 
personal communication, 2011).  
 
Hyperbaric oxygen therapy in  
Newfoundland and Labrador 
 
The HBOT facilities for Newfoundland and Labrador 
are located in the Health Sciences Center (HSC) in 
St. John’s.  Eastern Health administers HBOT 
through the Cardiac/Critical Care Program, with a 
mandate to serve the whole province.  Facilities 
currently include one multi-place chamber that can 
take up to six patients and two mono-place 
chambers.  The multi-place chamber is located in 
the northeast corner of the ground floor of the HSC, 
next to the medical school and MEDICOR. However, 
the multi-place chamber was not operational 
between 2009 and 2012.4  Until recently, the two 
mono-place chambers were housed in custom 
trailers located outside the northeast exit; they 
have now been moved inside the facility. 
 
 
At present, core staff serving the HBOT facilities 
consists of two physicians, a treatment or dive 
supervisor, a technical analyst and a patient care 
coordinator. Additional clinicians from other units 
within Eastern Health, such as respiratory therapists 
(RT) or Intensive Care Unit (ICU) nurses, participate 
on a case-by-case basis. At time of writing, HBOT 
capacity is limited to the two mono-place chambers 
and consists of approximately six treatments per 
week.  With additional staff support, full use of the 
multi-place chamber and the relocation of the 
mono-place chambers inside the HSC, the facilities 
could, we have been advised, provide up to seventy 
treatments per week.  
  
_________________________ 
4
 The multi-place chamber was first closed as the result of trained staff shortages, and later due to a contamination episode.  
14 
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There have been some gaps in HBOT record-keeping 
and in the monitoring of clinical data. The data that 
do exist are not considered reliable. Nevertheless, 
HBOT staff members are confident that the number 
of appropriate elective patients with non-healing 
wounds, as well as the cumulative number of 
treatments they are receiving, is significantly higher 
than the number of patients and treatments for 
emergency cases. Emergency patients typically 
undergo one to three HBOT treatments in total. The 
average number of emergency patients is reported 
to be no more than twenty per year. Elective 
patients, including patients with non-healing 
wounds, average twenty treatments for a full 
course of hyperbaric oxygen therapy. The number 
of elective patients treated has varied considerably 
over the past ten years, for two key reasons.  The 
first is the intermittent availability of staff to 
oversee and administer the multi-place chamber. 
The second involves closures of the multi-place 
chamber for significant periods as the result of 
technical problems or contamination. In Newfound-
land and Labrador, patients with non-healing 
wounds are referred for HBOT most often through 
specialists, such as dermatologists or orthopedic 
surgeons, involved in the treatment of the wound 
and/or treating underlying medical condition(s).  
Primary care physicians may also refer patients  
 
directly.  In practice, most patients will be seen first 
by a specialist in order to assess the wound, any 
underlying medical conditions, and any additional 
co-morbidity.  Nurses, especially wound-care and 
community health nurses, may act as catalysts for 
referral by bringing potential HBOT patients to the 
attention of their primary care physicians (Wells, C. 
Research Coordinator, Western Regional School of 
Nursing, personal communication, 2010).  Although 
a provincial committee on wound care has recently 
been established, at present there are few 
standardized wound-care protocols for non-healing 
wounds. 
Despite the lack of data, there is broad consensus 
amongst healthcare professionals that a significant 
number of patients with the types of difficult 
wounds suitable for hyperbaric oxygen therapy are 
not currently receiving this treatment.  Further-
more, cases requiring hyperbaric oxygen therapy for 
difficult wounds are expected to increase in future 
as a result of various trends: an aging population; 
expected increased prevalence of diabetes and 
obesity; and other medical factors such as the 
introduction of higher intensity radiotherapy 
treatments that are more likely to cause delayed 
radiation-induced injuries (DRII). 
 
What research did we look for?  
 
The health conditions included in this project were 
selected through consultation among the project 
team, our health system partners, and CADTH.  Of 
particular interest was the fact that HBOT is not 
included in the standard of care for so-called elec-
tive uses of HBOT for chronic conditions. This con-
trasts with emergency conditions (e.g., carbon mon-
oxide poisoning, gas embolism or gas gangrene) 
where HBOT is the standard of care.             
Standards of care for difficult wounds in general do 
not include HBOT, despite many types of wounds 
being approved by hyperbaric medicine organ-
izations. The specific forms of difficult wound 
healing that are included in this report are: diabetic 
foot ulcers, pressure ulcers, delayed radiation-
induced injury, thermal burns, skin grafts and flaps, 
and revascularization after organ transplantation. 
15 
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The search for, and identification of, evidence for 
this project were carried out by CADTH’s Health 
Technology Inquiry Service (HTIS). Their 
methodology for identifying evidence, like the 
approach traditionally used by CHRSP, focuses 
primarily on high level research, including sys-
tematic reviews, meta-analyses, health technology 
assessments (HTA), and very recent high quality 
primary studies such as randomized controlled 
trials. Like CHRSP, HTIS’s methodology includes 
searching periodical indexes for published articles 
as well as grey (not commercially published) 
literature sources.  A list of the health evidence 
databases used is available on the CADTH website.5   
The main difference in methodology between 
CHRSP and CADTH is that HTIS will exclude a given 
review paper where a more recent paper has been 
published that captures the same evidence as the 
older paper, and where the more recent review is 
judged to be as good, or better, in terms of 
methodological rigor (CADTH Report, “Hyperbaric 
Oxygen Therapy for Difficult Wound Healing:  A Sys-
tematic Review of Clinical Effectiveness and Cost 
Effectiveness” p 21). 
For this project, CADTH carried out the following 
searches (see CADTH report “Hyperbaric Oxygen 
Therapy for Difficult Wound Healing:  A Systematic 
Review of Clinical Effectiveness and Cost  
Effectiveness” for details of the search, pp 15-20, 
available at www.nlcahr.mun.ca/chrsp): 
 Key word and MeSH term searches were 
conducted for the health indicators of interest, 
for 2005 to 2010, of the following periodical 
indexes and databases: OVID Medline, OVID 
Medline In-Process & Other Non-Indexed 
Citations, EMBASE, PubMed, and the Cochrane 
Library. 
 Grey literature was identified by searching the 
websites mentioned above, as well as by web 
searches of related professional associations and 
additional specialized databases. 
 The foregoing searches were supplemented by 
general web searches (e.g., using Google 
Scholar), hand searching the bibliographies of 
identified references, and consultation with 
individuals and agencies involved with the topic 
in question.  
 Search results were screened based on 
information in the title and abstract of the 
article, and articles were then selected based on 
a full reading of the entire article. Both stages 
were carried out by two independent reviewers 
based on the following criteria (CADTH Report, 
“Hyperbaric Oxygen Therapy for Difficult Wound 
Healing:  A Systematic Review of Clinical 
Effectiveness and Cost Effectiveness” p5): 
 
 the study had to assess the clinical 
effectiveness, efficacy or economic 
effectiveness of HBOT for one or more of 
the eligible criteria; 
 the study design had to include a systematic 
review component (i.e., health technology 
assessment, systematic review or meta-
analysis) with at least two reviewers 
selecting studies and/or analyzing the data, 
or it could be a randomized clinical trial, or 
an economic evaluation;  
 the study had to be in English, peer-
reviewed, and published within the last five 
years.  
Searches by HTIS initially identified 314 references 
(see Figure 4). Screening reduced the number of 
references to sixty-three potentially relevant ones, 
from which thirteen were finally selected.
_________________________ 
5  http://www.cadth.ca/index.php/en/cadth/products/grey-matters 
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Of the thirteen included studies, seven were HTAs, 
(19-25) five were systematic reviews, (26-30) and 
one was a randomized controlled trial (see Figure 
4). (31)  Three of the HTAs were in languages other 
than English, for which only an English version of 
the executive summary was used in the synthesis. 
(21,23,25)  Four HTAs studied HBOT as adjunctive 
therapy for multiple categories of health indi-
cations. (19,23-25) The remainder of the included 
studies focused on a single category of health 
indications. Following is a breakdown of the types 
of review identified, according to health condition:  
 Diabetic foot ulcers: two HTAs, (20,22) two 
systematic reviews, (27,29) and one  RCT; (31) 
 Delayed radiation-induced injury: three 
systematic reviews; (26,28,30) 
 Thermal burns: one HTA; (21) 
 Skin grafts & flaps: no exclusive references; 
 Revascularization after organ transplantation: 
no exclusive references. 
The results of this literature search were 
synthesized by HTIS and independently reviewed by 
a clinical expert in the field. 
17 
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6  
In contrast, a significant amount of HBOT research is supported by the armed forces, both in Canada and the U.S.A. 
Accordingly, the topics that are studied tend to be quite different, with a focus on young healthy men in combat, 
peacekeeping and other related situations.  
 
What is the evidence?  
 
General comments about the evidence 
The existing systematic review literature for 
hyperbaric oxygen therapy for difficult wound 
healing has several inherent limitations. The first, 
and most significant, is the lack of large-scale 
randomized controlled trials. Interviews with local 
experts suggest two key reasons for this: difficulties 
coordinating the multi-site studies that would be 
required to provide an adequate number of 
research participants, and gaps in funding 
opportunities for both HBOT research and wound 
healing research (K. LeDez, President, Undersea & 
Hyperbaric Medical Society—Canadian Chapter, 
personal communication, 2011). The gap in 
research funding in Canada is an ongoing issue, 
since none of the Canadian Institutes of Health 
Research have an explicit mandate for hyperbaric 
medicine or wound healing (K. LeDez, personal 
communication, 2011).6  
Applying the findings from existing research to the 
HBOT facilities in St. John’s also has inherent 
limitations based on variability in the delivery of 
services.  For this study, the most important sources 
of variability involve differences in the degree to 
which HBOT is integrated into a wound-care 
program and the availability of support services for 
patients undergoing weeks or months of treatment. 
The greater the degree of integration, the more 
likely it becomes that patients will be treated in a 
timely manner, that they will be suitable patients 
for HBOT, that relevant patient information will be 
shared among health service providers, and so 
forth. The availability of support services will 
increase the likelihood that a patient will complete 
his or her full course of treatment, which is a key 
determinant of positive health outcome.  
For example, at Hôtel Dieu de Lévis outside Quebec 
City, the HBOT facility contains modern mono-
chambers that are accessible by acute-care patients 
and patients with limited mobility. The HBOT facility 
is located adjacent to a ‘complex wound clinic’ and 
shares with it a referral and booking system as well 
as some medical staff. The intensive care unit is 
located in the same wing of the hospital, two floors 
down. For accommodations, patients are referred 
to a non-profit hospice that is directly across the 
street from the hospital. The hospice offers low-
cost rooms for extended stays and access to a 
common kitchen area for guests to keep food and 
prepare meals (C. Boutin, Head of the Respiratory 
and Hyperbaric Department, Centre de médecine 
de plongée du Québec, personal communication, 
2011). As a result, research that relies on data from 
this facility and others like it may result in health 
outcomes that are better than what can be 
reasonably expected from the St. John’s HBOT 
facility, where there is less service integration and 
fewer supports are offered to patients. 
Pressure ulcers and diabetic foot 
ulcers 
The incidence of foot ulcers among people with 
diabetes is estimated to range from 1.0% to 4.1%, 
while the lifetime risk ranges from 15% to 25%. 
(27,32) The most severe health outcome from 
diabetic foot ulcers is amputation, which is 
estimated to occur in approximately 0.2% of adults 
with diabetes or about 3,000 in Canada.(33) 
Approximately 85% of amputations carried out in 
Canada are the result of a non-healing foot ulcer 
and an estimated 50% to 69% of amputees with 
diabetes die within five years.(34)     
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The number of times individual references were cited by the included review studies, by type of reference cited:  
 Legend: 
All types 
HTA 
Systematic review 
Primary Research 
Figure 5: Article analysis for HBOT for diabetic foot ulcers.  
 
Figure 6: Article analysis for HBOT for delayed radiation-induced injury (DRII). 
Figure 7: Article analysis for HBOT for thermal burns. 
Figure 8: Article analysis for HBOT for skin grafts and flaps. 
 
 
About the Article Analysis Figures: 
 
These article analyses indicate the 
degree of overlap of evidence 
among the included systematic 
reviews and HTAs included in this 
report.  
 
Systematic reviews with a high 
degree of overlap are synthesizing 
the same primary studies and 
would be expected to have 
convergent findings.  
 
Systematic reviews with a low 
degree of overlap are synthesizing 
different primary studies, and may 
or may not be convergent.  
 
Each bar cluster in the graphs 
indicates the number of times that 
a primary research study article 
was cited by the included 
systematic reviews.  
 
Articles that are only cited once 
represent no overlap; articles cited 
twice or more represent overlap. 
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Patients who have amputations also experience a 
significant decrease in quality of life and increased 
risk of injury.(35)  The main cost drivers for diabetic 
foot ulcers are treatment, co-morbidity, injuries 
related to an amputation, and subsequent ampu-
tations. (36) Research from Ontario estimates the 
average cost of treating a diabetic foot ulcer to have 
risen to $8,000 in 2007, up from a cost of $4,595 in 
1998. The average cost of treating an infected dia-
betic foot ulcer is estimated to be $17,000. (37,38) 
Newfoundland and Labrador has the highest 
prevalence rate of diabetes in Canada, with an 
estimated 47,000 cases in 2010.(39) An estimated 
26,000 new cases are expected between 2010 and 
2020.(39)  Based on the predicted rates cited above, 
an estimated 7,050 people with diabetes in the 
province will experience some form of foot ulcer 
during their lifetime, and nearly 100 will require 
some type of amputation. Data from the New-
foundland and Labrador Centre for Health Infor-
mation (NLCHI) indicate that, on average, 158 
patients with diabetes are admitted to hospital for 
diabetic foot ulcers each year.  Statisticians at NLCHI 
report that this number is understood to represent 
the most severe cases and accounts for only a 
portion of the estimated 15% of persons with 
diabetes who will develop lower-extremity ulcers 
over their lifetime (J. Dowden, Statistician, NL 
Centre for Health Information, personal commu-
nication, 2010). The burden of disease represented 
by diabetic foot ulcers in Newfoundland and 
Labrador, in terms of either clinical or cost out-
comes, has not been estimated. 
CADTH identified eight review papers, including six 
HTAs (19,20,22-25) and two systematic reviews 
(27,29) as well as one RCT (31) that addressed 
diabetic foot ulcers. The eight review papers cited a 
total of sixty-five individual publications. Forty-two 
of these publications studied clinical health 
outcomes and twenty-three studied economic 
outcomes.  CADTH also identified one review paper 
(24) that addressed pressure ulcers. This review 
paper cited a total of three individual publications 
based on one RCT. Figure 5 provides an article 
analysis of references for diabetic foot ulcers cited 
among the included studies for this report. 
Three CADTH references are English abstracts of 
French, German or Spanish language HTAs which 
did not contain enough information to be assessed 
for this report in terms of methodological 
quality.(21,23,25)  
Five of the remaining reviews had high quality 
methodologies, as rated by the AMSTAR7 scale:  
 De Laet et al.  8/11(19)  
 Ritchie et al.   7/11(24)  
 Hailey et al.   8/11(20)  
 MAS    7/11(22)  
 Hinchliffe et al.   7/11(29)  
 
Some references received low AMSTAR scores:  
 Chow et al.   4/11(27) 
 Cancer Care  
Ontario’s Hyper- 
baric Oxygen Therapy  
Working Group  
(HOTWG)    2/11(27,30)  
  
_________________________ 
7 
AMSTAR scores range from 0 to 11, with the following score categories: Low=0 to 4, Middle=5 to 7, High=8 to 11 
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Before reviewing the findings, an issue concerning 
terminology should be addressed. The body of the 
text in the original CADTH report refers to ‘diabetic 
pressure ulcers.’  This term is a misnomer that 
requires correction. 
 
PubMed does not include a Medical Subject 
Heading (MeSH) for ‘diabetic pressure ulcer.’  
However, the MeSH term ‘Pressure Ulcers’ is 
defined as: “ulceration[s] caused by 
prolonged pressure on the skin and 
tissues when one stays in one 
position for a long period of time” 
(PubMed, 1963/2006).  
 
In contrast, the MeSH term ‘Diabetic 
foot ulcer’ is defined as: 
“[a] common foot problem in 
persons with diabetes mellitus, 
caused by any combination of 
factors such as diabetic 
neuropathies; peripheral vascular 
disease; and infection. With the loss of sensation 
and poor circulation, injuries and infections often 
lead to severe foot ulceration…” (PubMed, 1994).  
  
Thus, ‘Pressure Ulcer’ and ‘Diabetic Foot Ulcer’ 
represent two distinct types of wounds produced by 
different mechanisms.  As a result, there is 
ambiguity in the terminology ‘diabetic pressure 
ulcer’ as used by CADTH. 
 
An analysis of the search strings, including 
systematic reviews and HTAs, as well as the 
individual studies synthesized by those reviews, 
indicates that the term ‘diabetic pressure ulcer’ 
refers exclusively to ‘Diabetic Foot Ulcer’ as defined 
by PubMed.   Accordingly, for purposes of clarity 
and consistency, this report refers to diabetic foot 
ulcers and does not use the term ‘diabetic pressure 
ulcers.’ 
 
The CADTH report finds sufficient evidence to in-
dicate that HBOT is “clinically beneficial and cost- 
effective as adjunctive therapy” for 
diabetic foot ulcers, but not for 
uncomplicated pressure ulcers (p. 
10). The main clinical outcomes of 
interest for diabetic foot ulcers are: 
wound healing, minor amputation 
and major amputation8 (see Table 
2).   For diabetic foot ulcers, there is 
broad agreement that HBOT is an 
effective adjunctive treatment that 
reduces the risk of major ampu-
tation. The available evidence, 
however, is limited in sample size 
and power. Nonetheless, one high-
quality and frequently cited Cochrane systematic 
review (40) quantifies the estimated relative risk 
(RR)9 of major amputation for patients treated with 
HBOT, compared with those who do not receive this 
treatment, to be 0.31  [95% CI 0.13, 0.71], resulting 
in less than half the number of major amputations. 
Further, the estimated number needed to treat10 
(NNT) is 4 [95% CI 3, 11] which is very low. The 
authors of this review paper caution that current 
findings are likely to change with further research. 
However, they state this caution with regard to the 
effect size, not the characterization of the treat-
ment as beneficial in terms of clinical and cost 
outcomes. (20,31,41) 
 
_________________________ 
8 
A minor amputation is defined as the removal of all or part of a hand or foot. A major amputation is the removal of all or 
part of a limb from above the wrist or ankle. 
9
Relative risk (RR) is the ratio of the probability of an outcome occurring in a treated or exposed group compared to the 
untreated or unexposed group (see Glossary).  
10 
Number needed to treat (NNT) is the number of patients who need to be treated in order to prevent one additional 
adverse health outcome (see Glossary). 
 
 
The CADTH report 
finds sufficient evidence 
to indicate that HBOT is 
“clinically beneficial 
and cost effective as 
adjunctive therapy” for 
diabetic foot ulcers, but 
not for uncomplicated 
pressure ulcers. 
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Diabetic Foot Ulcers:  Clinical Outcomes and Effectiveness of HBOT 
Outcome Quality 
of 
Review 
(AMSTAR) 
Evidence 
Conclusion: finding 
Major Amputation 
Clinical 
Effectiveness 
 
 
 
 
 
 
8 
8 
8 
7 
7 
 
7 
7 
7 
n/a 
n/a 
Decrease in risk: statistically significant evidence RR 0.31 [95%CI 0.13, 0.71]. (19) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (19) 
Decrease in risk: HBOT 11% vs controls 32%, “more effective than standard care.” (20) 
Decrease in risk: “therapeutic efficacy [is] suggested.” (24) 
Decrease in risk: statistically significant evidence RR 0.31 [95%CI 0.13, 0.071]. (22) 
Number Needed to Treat (NNT) to avoid amputation = 4 [95% CI 3 to 11]. (22) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (22) 
Decrease in risk: systemic HBOT reduced rates of major amputation, but not topical HBOT. 
Caution: sensitive to change with further research, lacking robust RCT evidence.(29) 
Decrease in risk: convergent evidence that HBOT was good for lesions. (25) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (25) 
Economic/ 
Quality of 
Life Impacts 
 
8 
8 
 
8 
8 
7 
 
7 
 
 
 
4 
 
4 
Unclear: Potential cost savings, requires better research. (19) 
More cost-effective: than standard of care (societal perspective), with nearly 20% less costs; if outcomes for 
HBOT were 10% worse it would still remain dominant therapy. (20) 
Breakeven point: $17,000 (CND), current cost $3,652. (20) 
Positive impact on QoL: significant increase in QoL (HBOT, 3.64, Standard care, -3.01). (20) 
More cost-effective: consistently cost-effective (societal perspective) compared to standard care or HBOT 
plus placebo. (24) 
More cost-effective: nearly 90% less costs compared to amputation, saving approximately $54,000 (CND). 
Relatively cost-effective from both payers’ and societal perspective (US research) with an incremental cost 
per additional QALY gained of approximately $27,310, $5,166, and $2,255 at the 1, 5, and 12-year periods. 
(22) 
More cost-effective: if used long term (societal perspective); Incremental costs per QALY for 1 year, $27,310 
(USD), 12 years $2,255. (USD). (27) 
Caution: Number of HBOT treatments/case, costs of amputations/case, costs of HBOT treatment had 
significant impact on cost-effectiveness. (27) 
Minor Amputation 
Clinical 
Effectiveness 
 
 
8 
 
8 
8 
8 
7 
7 
Possible increase in risk: indications for increased risk RR 2.20 [95%CI 0.56, 8.72], not statistically/clinically 
significant. (19) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (19) 
Possible increase in risk: HBOT 27% vs controls 15%, , not statistically or clinically significant. (20) 
Possible increase in risk: not statistically or clinically significant. (24) 
Possible increase in risk: estimates 1 minor amputation for every 11 patients treated with HBOT. (22) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (22) 
Wound Healing 
Clinical 
Effectiveness 
 
 
 
 
8 
8 
8 
7 
7 
7 
Improved wound healing: 33% greater decrease in wound size, [95%CI 18.97, 47.03]. (19) 
Caution: very sensitive to change with further research, drawn from single study with N=16. (19) 
Improved wound healing: HBOT 83% vs controls 43% (significance not calculated). (20) 
Insufficient evidence. (24) 
Improved wound healing. (22) 
Insufficient evidence. (29) 
Economic/ 
Quality of 
Life Impacts 
8 
 
7 
Possible shorter hospital stay: HBOT: 47.1 days (range 43.2 - 57.6 days)|Control: 56.9 days (range 50.8 -72.8 
days). (20) 
Insufficient evidence. (24) 
Pressure Ulcers:  Clinical Outcomes and Effectiveness 
General 
Clinical 
Effectiveness 
7 
n/a 
Insufficient evidence. (24) 
Not recommended (23) 
Table 2: Evidence for clinical and cost effectiveness of HBOT for diabetic foot ulcers 
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One paradoxical consequence of the reduction in 
risk for major amputation in patients with diabetic 
foot ulcers treated with HBOT appears to be an 
increase in the risk for minor amputation. It is 
widely interpreted that this documented (but not 
statistically significant) increase in minor 
amputations is reflective of the mitigating effect of 
HBOT on diabetic foot ulcers. While HBOT reduces 
the degree of severity of the wound, it does not 
entirely reduce the risk for any amputation.  
The main economic outcomes of interest for the 
treatment of diabetic foot ulcers with HBOT are 
those of cost effectiveness11, cost utility12 and 
length of hospital stay.  The literature reviewed was 
consistent in finding HBOT to be cost-effective from 
a societal perspective when compared with 
standard of care or placebo. The quantification of 
cost effectiveness is complicated by factors 
including differences in health insurance systems 
between countries and access to additional care 
within regions and population sub-groups. 
Estimates from Canada suggest that HBOT for 
diabetic foot ulcers results in 20% lower costs 
overall compared to standard treatment and 90% 
lower costs compared to amputation.(20,22,24,27)  
Chow et al. caution that the cost of amputations 
and the number of treatments per case have a 
significant impact on cost effectiveness.(27) 
However, Hailey and colleagues (20) find that HBOT 
would still be the most cost-effective treatment for 
diabetic foot wounds, even if clinical outcomes 
were 10% less beneficial to the patient.  The same 
authors also found that the costs of HBOT would 
need to rise to $17,000 per patient in order for 
HBOT to be deemed less cost-effective than the 
current standard of care, which they estimated to   
  
 
 
 
 
be an average of $3,652 per patient. Fewer reviews 
studied cost utility but, among those that did, there 
is convergent evidence indicating that HBOT 
provides greater quality of life (QoL) outcomes than 
the standard of care.  In one high-quality HTA from 
Canada, (20) the authors found a statistically 
significant improvement in QoL scores resulting 
from HBOT. Research evidence from the U.S.A. 
indicates that, for HBOT treatment of diabetic foot 
ulcers, the additional costs per QALY range from 
$27,310 for the first year to $2,255 over a 12-year 
period. Fewer still of the included studies 
considered length of hospital stay as a distinct 
health economic variable, but in considering the 
effectiveness of HBOT in wound healing for diabetic 
foot ulcers, Hailey and colleagues found a decrease 
in hospital stay of 17% or 9.8 days.(27) 
Insufficient evidence was available to evaluate the 
clinical or economic benefits of HBOT for pressure 
ulcers. 
Delayed radiation-induced injuries 
Delayed radiation-induced injuries (DRII) may arise 
from any form of radiation therapy for cancer. 
These injuries are categorized as a form of 
‘radiological disorder’ and accounted for 291 
patients and 439 hospital separations in 
Newfoundland and Labrador between 2002-2003 
and 2007-2008. A detailed analysis of the specific 
types of delayed radiation-induced injuries 
encountered in the province is not available. 
Interviews with local experts indicate that the 
number of admitted patients underestimates the 
total number of patients with DRII since many, if 
not most, are treated as outpatients (K. LeDez, 
President, Undersea & Hyperbaric Medical   
 
 
 
_________________________ 
12
 Costs-effectiveness study: the monetary costs of an intervention are considered in terms of a single common health 
outcome that is measured in natural units. In the case of HBOT, outcomes may include: wound resolution, major 
amputation, and graft revascularization. 
13 
Cost-utility study: the monetary costs of an intervention are considered in terms of a single outcome or of multiple 
outcomes that are valued in relative terms. The combined outcome is measured in units that capture both the quantity 
and quality of the effects of the intervention. The most common measure is the quality-adjusted life-year or QALY (see 
Glossary). 
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Society, Canadian Chapter, personal commun-
ication, 2011).  In addition, predicting the number 
of potential DRII patients who will be eligible for 
HBOT is complicated by various factors, including 
new developments in oncology treatment, changes 
in survival times for treated patients, and increases 
in rates of diagnosis. Our interviews also revealed 
that the number of specific HBOT referrals for DRII 
appears to have risen recently due to some 
increases in the dosage of radiation being used to 
treat certain cancers and a higher level of aware-
ness about using HBOT as an adjunctive therapy for 
DRII.  
HBOT research has focused mainly on DRIIs in two 
types of cancers: soft tissue injuries from pelvic 
region cancer radiation treatments and bone-
related injuries from head and neck cancer 
radiation treatments.  
Pelvic region DRIIs include radiation proctitis and 
radiation rectitis, which may occur as a result of 
radiation treatments for cancer of the prostate, 
testis, ovary, cervix, uterus, urinary bladder or 
rectum. The incidence of radiation proctitis/rectitis 
is strongly influenced by the type of radiation 
therapy used and the amount of radiation absorbed 
by the patient. Depending on the specific 
technique, incidence rates have been estimated 
from 5% to 20%.(42,43)  Incidence rates of many 
pelvic-region cancers, such as prostate or ovary 
cancer, increase with age. Consequently, rates of 
these cancers and related side-effects such as 
radiation proctitis/rectitis are expected to increase 
with the aging of the population in Newfoundland 
and Labrador.  
Head and neck region DRIIs mainly affect the jaw 
and teeth. Similar to radiation proctitis/rectitis, 
head and neck DRIIs are strongly influenced by the 
type of radiation treatment and the amount of 
absorbed radiation. The incidence of mandibular 
osteoradionecrosis,(44,45)  (i.e., degeneration of 
the jaw bone following radiation treatment) has 
been estimated to range between 1.8% at doses of 
6,000 cGy to 9% at 7,000 cGy.(44)  
CADTH identified four HTAs (19,23-25) and three 
systematic reviews (26,28,30) that addressed HBOT 
for the treatment of a broad range of DRII. The 
seven review papers cited a total of forty-four 
individual studies. Forty-three studies examined 
clinical health outcomes and three examined health 
economic outcomes (Figure 6). Two of the 
publications referred to by CADTH are English 
summaries of French and Spanish language HTAs 
and were not assessed in terms of methodology. 
(23,25) The two remaining HTAs and two systematic 
reviews scored high on the AMSTAR scale:  
 De Laet et al.  8/11(19) 
 Ritchie et al. 7/11(24) 
 Denton et al.  8/11(28) 
 Bennett et al.  9/11(26) 
 
One systematic review scored low: HOTWG, 
2/11(30).   
 
A range of DRIIs are possible candidates for adjunct-
ive HBOT (Table 3). The main clinical outcomes of 
interest across these conditions are: decreased 
inflammation and/or infection, successful resolution 
of injury, and improved quality of life scores.  
 
The CADTH report finds evidence that adjunctive 
HBOT is “beneficial” for osteoradionecrosis and 
radiation rectitis/proctitis; however the report does 
not find the strength of the evidence to be 
sufficient to call for the routine use of HBOT for 
these conditions. However, our local experts 
pointed out that ‘routine use’ of HBOT in New-
foundland is quite rare: most patients with non-
healing wounds are referred for HBOT only after 
having undergone a series of other unsuccessful 
treatments.  
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Delayed radiation-induced injury 
Outcome Quality 
of 
Review 
(AMSTAR) 
Evidence 
Conclusion: finding 
General 
Clinical 
Effectiveness 
n/a 
2 
“Controversial.” (23) 
Insufficient evidence: Limited research available and conflicting evidence. (30) 
Radiation rectitis/proctitis 
Clinical 
Effectiveness 
9 
 
 
8 
8 
7 
 
 
n/a 
Improved healing: compared to placebo across several primary outcome measures including symptoms and 
resolution, secondary measures included mortality, co-morbidity and QoL scores (RR: 2.7, [95%CI 1.2 to 6.0] 
p = 0.02). Number Needed to Treat (NNT) = 3. (26) 
Improved healing: compared to placebo. (28) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (28) 
Improved healing: statistically significant greater likelihood of healing or improvement of proctitis  
 (RR=2.67; 95% CI: 1.19, 5.99; p=0.02), significantly improved SOMA-LENT scores (5.00 in the HBOT group 
versus 2.61 in the sham HBOT group (p=0.0019)). (24) 
Improved healing. (25) 
Osteoradionecrosis, head & neck soft tissue (as treatment) 
Clinical 
Effectiveness 
9 
 
9 
 
8 
 
 
 
8 
7 
7 
2 
Improved healing: despite negative findings in most recent RCT, evidence indicates better outcomes with 
HBOT treatment. (26) 
Caution: Limited research available, and differences in measuring clinical health outcomes falsely indicating 
divergent conclusions. (26) 
Improved healing: complete resolution (RR 1.41 [95% CI 1.14, 1.75]); head and neck wound dehiscence (RR 
8.67 [95% CI 2.73, 27.49]), complete mucosal cover healing (RR 1.38 [95% CI 1.19, 1.61]), healing of tooth 
sockets after tooth extraction (RR 1.35 [95% CI 1.08, 168]); further research to clearly establish clinical 
effectiveness (from one SR with 6 RCTs [447 patients]).  (19) 
Caution: further research needed to clearly establish clinical effectiveness. (19) 
Improved healing: head and neck wound dehiscence. (24) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (24) 
Insufficient evidence: Limited research available. (30) 
Economic/ 
Quality of 
Life Impacts 
8 
 
7 
 
Possibly cost-effective: available evidence indicates decreased costs, but insufficient to generalize (from 
two studies). (19) 
Possibly cost-effective: available evidence indicates decreased costs, but insufficient to generalize (from 
two studies). (24) 
Osteoradionecrosis, head & neck soft tissue (as prevention) 
Clinical 
Effectiveness 
7 
7 
 
7 
Effective prophylaxis: more effective than antibiotics (RR=1.4, 95% CI: 1.1, 1.7; p=0.009). (24) 
Effective for dental implants: fewer failures with HBOT compared to controls (8.1% versus 53.7%; 
p=0.0009). (24) 
Caution: sensitive to change with further research, lacking robust RCT evidence. (24) 
Urinary Bladder 
Clinical 
Effectiveness 
9 
7 
2 
No available evidence. (26) 
Insufficient evidence (interstitial cystitis). (24) 
Insufficient evidence: Limited research available (interstitial cystitis). (30) 
Breast/chest wall 
Clinical 
Effectiveness 
7 
2 
No available evidence. (24) 
Insufficient evidence: Limited research available. (30) 
Bowel 
Clinical 
Effectiveness 
7 No available evidence. (24) 
Neurological tissues 
Clinical 
Effectiveness 
7 
7 
Insufficient evidence and/or no significantly improved healing (brain irradiation).(24) 
No significantly improved healing (brachial plexopathy). (24) 
Table 3: Evidence for clinical and cost effectiveness of HBOT for delayed radiation-induced injury 
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The evidence cited by the CADTH report for HBOT 
treatment of radiation proctitis/rectitis indicates 
consistent, statistically significant improvements 
across a range of clinical outcomes, including de-
gree of healing, resolution of injury, quality of life 
and improved SOMA-LENT13 scores (see Table 3). 
Similarly, the evidence for HBOT treatment for pre-
vention of head and neck injuries to soft and bony 
tissue indicates improvement, but the findings are 
of limited strength. For example, De Laet and coll-
eagues (19) found improved healing with HBOT 
treatment of osteoradionecrosis across several 
clinical health outcomes; however, the evidence is 
taken from a limited number of studies with few 
participants and sometimes incommensurate out-
come measures.  
It should also be noted that the research studies on 
adjunctive HBOT for other types of DRII are con-
sistent in finding no significant negative effects. 
Instead, where data is available, there are con-
sistent and repeated findings of small improve-
ments in wound healing. The lack of statistically 
significant positive findings should not be inter-
preted as evidence that the treatment is not effect-
tive; rather, it may be the case that the existing 
studies have too few research participants to stat-
istically detect an actual treatment effect.  In other 
words, while there is insufficient evidence to indi-
cate HBOT is an effective adjunctive treatment for 
other forms of DRII, it should not yet be ruled out as 
ineffective. 
The literature included in the CADTH synthesis 
sought out evidence for other forms of delayed 
radiation-induced injuries, including to the bowel, 
urinary bladder, breast and chest wall, and to 
neurological tissue. In these cases, there was either 
insufficient evidence or no evidence at all due to a 
lack of published research.   Very little health eco-
nomic research has been carried out on the cost- 
effectiveness of HBOT for DRII.  Ritchie et al. and De 
 
 
Laet et al. published findings on cost effectiveness 
from the same studies, (24,45) and both suggested  
that using HBOT for osteoradionecrosis would gen-
erate savings from the societal perspective as com-
pared to a “conservative” treatment option. Re-
duced hospital stays and fewer future health comp-
lications were the main drivers for these savings. 
Thermal burns 
When compared with other injuries, relatively few 
cases of severe thermal burns occur in Canada.  One 
study estimated the number of children admitted to 
hospital for burns at 12.6/100,000.(46)  Among the 
adult population admitted to hospital for burn 
treatment, North American estimates are 30 per 
100,000 patients, with approximately 4.2/100,000 
requiring specialized burn treatment/ admission to 
a burn-care centre.(47) However, costs for treating 
severe burns are often estimated to be among the 
highest for all injuries.(48) 
Interviews with local experts indicate that severe 
burns are now less prevalent in Newfoundland and 
Labrador than they were twenty years ago, and that 
the drop in numbers can be attributed mostly to the 
decrease in use of deep fat fryers in the home (M. 
Cashin, Wound Care Consultant, Acute Care, 
Eastern Health, personal communication, 2011). 
Data for severe burns in the province are limited 
mainly to children. Between 1995 and 2001, NLCHI 
reports that there were 157 hospital separations for 
children aged 0 to 16 years with severe burns. (49) 
Burns were more common among aboriginal 
children - 84.3 per 100,000 - than among those of 
European descent- 19.0 per 100,000.  
CADTH identified five HTAs (19,21,23-25) that 
studied HBOT for the treatment of thermal burns 
(Table 4). The five review papers cited a total of 
seventeen individual references. Sixteen references 
studied clinical outcomes and one studied health 
economic outcomes only (Figure 7). 
26 
_________________________ 
13 
SOMA-LENT is a scale to measure Late Effects on Normal Tissue (LENT) from radiation therapy, from several 
perspectives: Subjective, Objective, Management, Analytic (SOMA). 
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Three of the CADTH references are English 
summaries of other language HTAs and could not be   
assessed in terms of methodology. (21,23,25) The 
two remaining HTAs scored high on the AMSTAR 
scale: De Laet et al. 8/11(19) and  Ritchie et al. 7/11. 
(24) In agreement with each of the included HTAs, 
the CADTH report finds insufficient evidence to 
support HBOT as a treatment for thermal burns. 
The most relevant evidence comes from a high-
quality and thrice-cited (19,24,25) Cochrane review 
by Villanueva and colleagues (50) that specifically 
focuses on HBOT for thermal burns. This systematic 
review searched for RCTs that compared HBOT for 
thermal burns against a control group and that 
reported on at least one out of nine possible health 
outcomes.14  Only two studies were identified that 
met the eligibility criteria; both studies were poor in 
methodological quality and had small sample sizes. 
Consequently, they did not provide adequate 
evidence to support or contradict the use of HBOT 
for thermal burns. This result is similar to that found 
in the other included systematic reviews. CADTH 
found what little research exists to be characterized 
by poor methodological quality and small study 
groups that do not provide the evidence base 
required to determine the clinical effectiveness of 
HBOT treatment for thermal burns. 
Skin grafts & flaps 
CADTH identified three HTAs that looked at HBOT 
for the treatment of skin grafts and skin flaps. 
(19,24,25) The three review papers cited a total of 
eleven individual references, all of which studied 
clinical health outcomes (Figure 8). 
 
 
Thermal burns 
Outcome Quality 
Of 
Review 
(AMSTAR) 
Evidence 
Conclusion: finding 
General 
Clinical 
Effectiveness 
7 
n/a 
n/a 
n/a 
Insufficient evidence. (24) 
Insufficient evidence. (25) 
Insufficient evidence: Evidence of reduced wound healing time, but not conclusive. (21) 
Not recommended. (23) 
Graft success 
Clinical 
Effectiveness 
8 
 
No improvement: No evidence for graft success (RR 2.00 [95%CI 0.50, 8.00]). (19) 
Mortality 
Clinical 
Effectiveness 
8 
n/a 
No improvement: No evidence for reducing mortality (RR 0.98 [95%CI 0.37, 2.64]). (19) 
No improvement. (21) 
Sepsis 
Clinical 
Effectiveness 
n/a Unclear: contradictory findings from two studies, neither significant. (21) 
Table 4: Evidence for clinical and cost effectiveness of HBOT for thermal burns 
 
________________________ 
14 
The studied health outcomes were: mortality, major morbidity, healing time, need for grafts and/or debridement, 
length of stay, pain scores, activities of daily living, and adverse effects from HBOT. 
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One of the CADTH references is an English summary 
of a French HTA and was not assessed in terms of 
methodology. (25) The two remaining HTAs scored 
high on the AMSTAR scale: De Laet et al. 8/11, (19) 
Ritchie et al. 7/11. (24)  In agreement with the 
included HTAs, the CADTH report concluded there is 
insufficient evidence to support or contradict HBOT 
treatment for skin grafts or for skin flaps (Table 5). 
 
Skin grafts and flaps 
Outcome Quality 
of 
Review 
(AMSTAR) 
Evidence 
Conclusion: finding 
General 
Clinical 
Effectiveness 
8 
 
7 
n/a 
Improved healing: compared to standard care, for acute soft tissue ischemia (based on 1 RCT) 
Caution: very sensitive to change with further research, lacking robust RCT evidence to form conclusion.(19) 
Insufficient evidence. (24) 
Not more effective: except in cases of radio-necrosis, as mentioned above.(25) 
 
Revascularization after organ 
transplantation: 
CADTH did not identify any research-based 
evidence for HBOT for post-transplantation 
revascularization (Table 6). Published articles in this 
field of research consist mainly of animal models or 
human case studies, neither of which provides an 
 
adequate evidence base for the purposes of this 
report. Nonetheless, there is growing basic bio-
medical evidence that suggests that HBOT should 
trigger biochemical, proteomic and genomic 
processes that would “condition” the donor’s organ 
to better withstand the stresses of the transplant 
procedures. (54) 
 
Revascularization after organ transplantation 
Outcome Quality 
of 
Review 
(AMSTAR) 
Evidence 
Conclusion: finding 
General 
Clinical 
Effectiveness 
7 
 
Insufficient evidence. (24) 
 
 
 
  
Table 5: Evidence for clinical and cost effectiveness of HBOT for skin grafts and flaps 
 
Table 6: Evidence for clinical and cost effectiveness of HBOT for post-organ transplantation revascularization 
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The Newfoundland and Labrador Context 
 
Throughout the course of this project, the specific characteristics of the province have been considered in relation 
to the research topic. Through individual interviews, as well as a panel discussion, we have identified contextual 
factors that may influence the relevance and applicability of the research-based evidence. Some of these factors 
have already been described and addressed in the body of the text. 
Following is a comprehensive and categorized table that lists factors of relevance to contextualization. 
 
 
Client-related factors 
Demographics 
 
Demographic trends in NL indicate an increase in the prevalence of risk factors for 
diabetic foot ulcers, including: an aging population, increasing rates of diabetes and 
overweight, and persistent high rates of smoking. The number of prospective NL 
patient referrals to HBOT for wound healing is expected to increase. 
 
 
Geographic/ cost factors 
for patients 
 
Patients who live significant distances from St. John’s must travel a long way to 
access HBOT for wound healing. These same patients also require accommodations 
in St. John’s for weeks or months at a time.  Lost time from work can be another 
significant out-of-pocket expense for patients. As a result of these geographic and 
cost factors, patients may leave St. John’s before their full course of HBOT 
treatment has been completed, which can be expected to decrease the 
effectiveness of the hyperbaric oxygen therapy.  
o The local HBOT team is experimenting with different treatment protocols 
for out-of-town patients that would reduce requirements for length of stay 
in St. John’s.  One new protocol would see patients being treated twice a 
day instead of once a day, reducing length of stay by 50%. 
o Tele-health services may be a useful means to consult with out-of-town 
patients about HBOT services prior to their arrival. 
 
 
Awareness 
 
The public is learning more about HBOT independently through media, hyperbaric 
and patient advocacy groups, and online sources.  Elevated awareness of HBOT as a 
treatment option may increase the rate of patients self-referring or directly 
requesting referrals from their physicians. Some of these patients may not be good 
candidates for HBOT and might put additional work demands on staff while 
decreasing the overall effectiveness of the facility. 
 
  Table 7: Factors of Relevance in Contextualization for Newfoundland and Labrador 
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Factors related to site of service/service design 
Location 
 
The HBOT facilities in the Health Sciences Centre are located outside of the patient-
care areas of the hospital.  This  may make accessing the HBOT chambers 
problematic for patients with limited mobility and especially challenging for patients 
arriving from outside the Health Sciences Centre: 
o Travel through public areas increases the risk of infections, especially for 
immune-compromised patients. Since many patients with non-healing 
wounds are immune-compromised, this is a serious concern for HBOT. 
o Increased travel, in general, for patients with non-healing wounds can 
exacerbate the wounds or worsen co-morbid conditions. This is especially 
the case for patients who are far from St. John’s or who are in-patients at 
other care centres in the city and require inter-facility transportation. 
o Entering and leaving the multi-place chamber is physically challenging and 
may exacerbate non-healing wounds.   
 
Design 
 
 
 
Problems in the design of the main oxygen line for the hospital are interfering with 
the delivery of oxygen to the mono-place chambers. As a result, the mono-place 
chambers are currently using replaceable oxygen canisters, a more expensive 
option. 
 
Directing patients 
 
 
Differing signage protocols between Eastern Health and Memorial University have 
presented challenges in providing adequate directional signs to guide patients to 
the hyperbaric oxygen facilities.  As a result, cost efficiency is compromised in two 
ways:  (a) Patients are more likely to get lost and be late for appointments and (b) 
employees at the facility are required to spend valuable treatment time guiding 
patients through the Health Sciences Centre to locate the facility. 
  
 
Factors related to health human resources 
Capacity 
 
At current available health human resource levels, capacity for HBOT operations 
exceeds actual utilization levels.  Cost efficiencies will improve when utilization of 
the facility increases to meet its operating capacity. 
 
Availability 
 
In the past, availability of appropriate human resources was a major factor in the 
ability to deliver HBOT services. As a result, past systems of service delivery saw a 
significant proportion of HBOT delivered at the end of the standard working day, 
which increased costs because personnel were working overtime hours.  There are 
now four additional physicians who have been trained to deliver and oversee HBOT 
treatments.  This development is expected to alleviate previous human resource 
capacity problems. 
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Factors related to health human resources 
(continued from previous page) 
Training and Safety 
 
There is currently a shortage of appropriately trained nurses and respiratory 
therapists to accompany unstable, intensive care, or critical care patients into the 
HBOT multi-place chamber.  This particular issue is compounded by the fact that, 
due to safety issues, personnel accompanying patients inside the multi-place 
chamber are limited to participating in one hyperbaric treatment per day.  As a 
result, cost effectiveness of the multi-place chamber, which can treat up to six 
patients per session, is limited.  
 
The cost effectiveness of the two mono-place chambers is also limited by the lack of 
specialized personnel available to attend patients.  However, unlike the multi-place 
chamber, personnel can attend multiple sessions throughout a day for the mono-
place chambers, which may result in increased cost effectiveness for this option. 
 
Pediatric cases 
 
Additional health human resources are required when treating pediatric patients 
with HBOT.  Currently, there are no specialized pediatric personnel or equipment 
available for the HBOT facilities. 
 
 
Record-keeping 
 
The efficiency of local HBOT is undermined by gaps in record-keeping and data 
collection that will require additional human resources support.  The ability to  
better monitor treatments will enable HBOT staff to identify strengths and 
weaknesses in facility operations and to tailor services to be more effective and 
cost-efficient. 
 
 
Education/Orientation  
 
There are challenges to raising awareness and building expertise for appropriate 
wound-care management among referring physicians, patients and health system 
administrators. There may be a requirement for increased human resources to 
support initiatives that will educate and orient relevant groups about HBOT in the 
province.  
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Factors related to organization and delivery of services 
 
Appropriateness of 
referrals 
 
While most referrals to the HBOT service are appropriate, a significant minority are 
not.  Inappropriate referrals can be expected to decrease the clinical effectiveness 
and/or cost effectiveness of HBOT: 
o In some cases, physicians in the province are either uneducated or 
misinformed about the approved medical conditions for HBOT or the 
clinical indications used to assess eligibility for HBOT. As a result, they may 
make inappropriate referrals or fail to make referrals in cases where HBOT 
is explicitly indicated. 
o Bed shortages can arise in acute-care facilities (particularly in St. John’s) 
due to a lack of appropriate wound-care beds or alternative discharge 
options.  As a result, admitted patients who have had extended hospital 
stays without noticeable progress in wound recovery may be referred for 
HBOT on the basis of mitigating bed shortages rather than being referred 
on the basis of their particular clinical indications. 
o Increased exposure to HBOT in medical school and through continuing 
medical education may improve levels of knowledge concerning 
appropriate referrals. 
 
 
Integration with wound-
care management 
 
HBOT for non-healing wounds is expected to be most effective when integrated into 
a standardized wound-care management program. Eastern Health and some of the 
other RHAs have established wound-care clinics, but lack a standardized wound- 
care program.  As a result, the effectiveness of HBOT may be lower than reported in 
the research literature.  
 
 
Acute-care vs. Chronic-
care approaches 
 
The current administration of HBOT in Newfoundland and Labrador places a dual 
acute-care/chronic-care service solely within an acute-care program (Emergency 
Ambulatory Care Services, Eastern Health).  Acute-care programs have mandates 
and objectives that are different from, and may be in conflict with, the chronic-care 
needs and goals of HBOT.  Furthermore, the chain of command between program 
administrators and the HBOT staff is not as robust as it could be and may need 
strengthening.15  These organizational factors may influence the implementation 
and delivery of HBOT services and consequently the clinical effectiveness and/or 
cost efficiency of the therapy.  
 
 
Service efficiencies 
 
Past systems for dealing with wound care, including the streamlining of products 
and services that were expected to improve cost efficiency and the integration of 
wound-care management with other services, appear to have been lost in the 
transition to the present regional health authority system. 
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15 
Local administrators identified a lack of knowledge about HBOT and expressed interest in a having a half-day seminar to 
explain the results of this study and to learn more about HBOT. 
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Other system factors 
 
Effective communications 
 
There are challenges in communication between family physicians and specialists 
treating patients with non-healing wounds. In particular, information related to 
previous and ongoing treatments is not always accurately shared and a common 
platform to share this information is lacking.  As a result, treatment planning may 
be less than optimal and the clinical outcomes less robust than expected. In 
addition, where some tests, treatments or consultations are repeated 
unnecessarily, the costs per patient may be higher than necessary. 
 
 
Capacity and chamber 
issues 
 
An increase in referrals, even if for appropriate patients, will not be absorbed into 
the present system easily. Increased capacity and a resolution to chamber 
functionality issues will be required to meet increased demand. 
 
 
Impact of emergency cases 
 
Emergency cases are unpredictable and have an impact on elective cases in terms 
of wait times and processing. Emergency cases can delay HBOT for elective 
treatments and decrease its efficiency. 
 
 
Economic factors  
 
Remuneration for multi-
place chamber vs. mono-
place chamber use 
 
A significant challenge to the cost effectiveness of HBOT services has been the 
existence of remuneration inequities in treating multiple patients simultaneously 
vs. treating one patient at a time.  The multi-place chamber is more cost-effective 
than the mono-place chambers since it can treat several patients simultaneously.  
However, until recently, physicians were remunerated at the full rate for only the 
first patient treated in the multi-place chamber and thereafter at a fractional rate 
for additional patients.  As a result, the more efficient HBOT chamber had been 
underutilized. 
 
 
Overtime 
 
Until recently, HBOT was typically delivered after standard work hours, requiring 
non-medical staff to be remunerated at overtime rates.  This issue arose from a 
disincentive to supervising physicians when it came to offering treatment during 
normal work hours; namely, they earned less administering HBOT than they did 
carrying out other clinical duties.  In turn, the overtime issue made the service less 
cost-effective, with the facilities being under-utilized during regular hours and 
patients being required to remain in hospital for longer than necessary. 
 
Costs borne by patients 
 
Out-of-pocket costs, including travel, accommodations and lost work time, may 
dissuade patients from obtaining timely and effective HBOT wound care (as 
mentioned above). 
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Political factors 
 
Requirement for a 
Canadian HBOT indications 
system 
 
In Canada, indications for HBOT are determined by the US-based UHMS. The UHMS 
does not use a strictly evidence-based system to include/exclude HBOT indications, 
and may be influenced by political factors within the US health system. A newly 
formed Canadian Chapter of the UHMS could provide a more flexible and 
appropriate set of indications for HBOT. 
 
 
Credentials 
 
Provincial credentialing for hyperbaric medicine is expected to increase the level of 
expertise, competencies and skill for relevant health professionals, which in turn is 
expected to increase the effectiveness of HBOT for all conditions, including non-
healing wounds. 
 
 
Public expectations for 
services 
 
The original impetus behind the recent upgrading of the facilities was public outcry 
over the unavailability of services. As the new HBOT services are implemented, 
public expectations for continued access to those services are likely to be high. 
 
 
Public awareness about 
HBOT uses 
 
Due to a lack of professional awareness about HBOT for chronic conditions, in 
particular, non-healing wounds, significant demand is expected to be consumer- 
directed. Non evidence-based claims of HBOT effectiveness for some conditions, 
(e.g., HBOT for cerebral palsy or autism) have been reported despite conclusive 
debunking (28 in WE). Awareness initiatives directed to the public are expected to 
help counterbalance these claims and mitigate public expectation for services. 
 
 
Impact of private services 
 
There have been rumors of a private facility being opened in Central 
Newfoundland and Labrador that may offer HBOT services for conditions that lack 
an evidence base or for which HBOT is not an indicated treatment. Such privately 
provided services could increase demand on publicly provided HBOT for conditions 
that are not supported by clinical evidence.  At present, there is no credentialing 
system for HBOT that would serve to protect the public from unqualified private 
service providers. 
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Implications for Decision Makers 
Evidence for the clinical and cost effectiveness of 
HBOT for difficult wounds, and the contextualization 
of this evidence for Newfoundland and Labrador, 
reveal several implications for decision makers: 
1. Hyperbaric oxygen therapy is expected to be a 
clinically effective adjunctive therapy for non-
healing diabetic foot ulcers for patients in 
Newfoundland and Labrador, in terms of both 
health outcomes (such as a reduction in major 
amputation) and quality of life outcomes. 
HBOT is also expected to be cost-effective 
from a societal perspective in treating such 
conditions.  
2. HBOT is expected to be a clinically-effective 
adjunctive therapy for delayed radiation-
induced injuries for patients in Newfoundland 
and Labrador who have been treated for 
cancers in the head, neck, and pelvic regions. 
It is unclear, however, whether HBOT for 
these difficult wounds is cost-effective.  
3. Existing research evidence does not support 
or contradict HBOT for other difficult wounds 
included in this study, namely: pressure 
ulcers, delayed radiation-induced injuries in 
parts of the body other than the head, neck 
and pelvic regions, severe thermal burns, skin 
grafts and skin flaps, or post-transplantation 
revascularization. 
4. The overall incidence of difficult wounds is 
expected to increase as a result of various 
trends, including increased life expectancies, 
higher prevalence of chronic disease, and 
improvements and/or changes in the 
treatment of cancer, diabetes and other 
chronic diseases. An increase in the number of 
patients that can be treated both effectively 
and efficiently with HBOT will improve its 
overall cost effectiveness. This economic 
impact will result from the fixed costs of HBOT 
being divided among a greater number of 
patients. Cost effectiveness also improves 
with faster and/or more complete healing of 
non-healing wounds. Improved healing 
decreases both direct and indirect costs to the 
healthcare system that would otherwise be 
incurred in treating such wounds.  
5. Clinical and cost benefits of HBOT for diabetic 
foot ulcers and DRII are contingent on the 
appropriate and timely referral of patients. 
Physician education will play a major role in 
maximizing appropriate referrals which, in 
turn, will have a positive impact on the clinical 
and cost effectiveness of the therapy.  
6. Implementing an integrated wound-care 
management program is expected to result in 
significant improvements to the clinical and 
cost effectiveness of HBOT. Establishing HBOT 
within an integrated wound-care program 
would also influence several contextual 
factors that are expected to have beneficial 
health and economic outcomes.  These 
contextual factors include: the site and design 
of the service (e.g., the distance between in-
patient areas, admitting, and the HBOT 
facilities), organization and delivery of services 
(e.g., appropriateness of treatment 
programs/referrals), and other system factors 
(e.g., more effective communications among 
healthcare providers). The review literature 
draws on evidence that tends to come from 
jurisdictions where wound management is an 
integrated service within the healthcare 
system. The lack of integration of wound 
management within other healthcare services 
and programs is expected to reduce overall 
clinical effectiveness and cost efficiency of 
HBOT for non-healing wounds when 
compared with reports from the review 
literature. 
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7. The overall scarcity of research on HBOT for 
non-healing wounds implies that future 
studies will have a significant impact on the 
evidence base.   For health conditions with 
insufficient evidence to support or 
contradict HBOT as effective, new research 
may provide more definitive answers. 
Decision makers should expect evidence for 
new applications of HBOT for chronic 
conditions and non-healing wounds. 
Our interviews with local experts and decision 
makers also revealed some problems related to 
governance in terms of HBOT in Newfoundland and 
Labrador.  Specifically, there were concerns from 
both practice and policy stakeholders that there is 
no obvious and appropriate administrative locus for 
HBOT within Eastern Health.  HBOT is not yet 
adequately utilized to warrant its own program 
within the health authority, serving only a small 
number of emergency cases and increasing 
numbers of patients with chronic conditions, while 
being administered through Ambulatory Acute 
Care.  At several meetings, it was suggested that 
education and orientation sessions for decision 
makers should be undertaken in an effort to explore 
the full range of HBOT services available and to 
identify any future problems and challenges 
anticipated for hyperbaric oxygen therapy in 
Newfoundland and Labrador. 
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